Integer reports Q3 adjusted EPS $1.43, consensus $1.36

Reports Q3 revenue $431M, consensus $440.63M.”Third quarter year to date, Integer (ITGR) delivered 10% sales growth and a 23% increase in adjusted operating income versus a year ago,” said Joseph Dziedzic, Integer’s president and CEO. “We expect 2024 sales growth of 10% to 11% with above-market organic sales growth of 7% to 8%. We are raising the midpoint of our full year adjusted operating income outlook by $4 million dollars, to 20% year over year, up from 18% in our previous outlook. The divestiture of Electrochem will make Integer a pure-play medical technology company and provides additional capital to invest in capabilities and capacity that support our targeted growth markets.”